Medical Device Import Legality and Customs Controls in Australia

1. Key takeaways

Australia has no separate import licence system for medical devices. Import legality derives from the fact that the kind of device is entered in the ARTG in that person’s name — importing an unentered device is a criminal offence carrying up to imprisonment for 5 years or 4,000 penalty units; and once TGA gives written notice to Customs, the device is treated under section 229 of the Customs Act 1901 as prohibited imports and prohibited exports.

• Import legality attaches to the ARTG entry, not to a company-level licence.
• Offence penalties run up to 5 years imprisonment or 4,000 penalty units in aggravated cases.
• A TGA notice to Customs converts the enforcement risk into seized goods.
• Certain devices require 20 working days advance notice before import, supply or export.
• Wholesale supply of an unentered device carries its own penalty of 120 penalty units.

The design is deliberate: the regulator does not police who may import, but what may be imported. That shifts the compliance burden from licensing authorities to the ARTG entry itself, and it makes entry hygiene — validity, coverage and payment status — the core of import compliance.

2. Legal basis

The provisions below cover the offence, the customs linkage, the wholesale offence, the entry-based legality test and the advance notice rule.

1. Therapeutic Goods Act 1989 (Act No. 21, 1990): section 41MI(1) — importing, exporting, supplying in Australia or manufacturing a device that is not entered in the ARTG is an offence; section 41MI(4) — where the conduct causes or is likely to cause harm, imprisonment for 5 years or 4,000 penalty units, or both; section 41MI(5) — in any other case, imprisonment for 12 months or 1,000 penalty units; section 41MIB — civil penalties.
2. Customs linkage: section 41MJ — after TGA gives written notice to Customs, the device is treated, under section 229 of the Customs Act 1901, as prohibited imports and prohibited exports.
3. Wholesale tier: section 41MK — wholesale supply of an unentered device attracts 120 penalty units.
4. No separate import licence: import legality derives from the entry of that kind of device in the ARTG in that person’s name (section 41MI(1)(b)(i)); the importer is itself a sponsor by virtue of section 3(1).
5. Advance notice for specific devices: Therapeutic Goods (Medical Devices) Regulations 2002, regulation 5.12 — Class 3/4 IVDs, in-house IVDs, self-test and near-patient testing IVDs, and spinal fusion implants must be notified 20 working days before the intended import, supply or export.
6. [practical estimate] No basis was found in Commonwealth therapeutic goods law for a claim that “importers must hold a separate licence”; warehousing and poisons storage requirements mostly fall under state and territory law.

3. Expert insights

Insight 1: the import permission is an attribute of the entry, not of the company. Australia does not issue import licences to companies; legality hangs on the ARTG entry. This means the same company may import product A lawfully and product B unlawfully — the outcome depends on the entry, not the enterprise. Portfolio growth therefore multiplies exposure silently: every new model must be checked against the entry that will carry it, before the purchase order is issued rather than after the goods are on the water.

Insight 2: section 41MJ connects administrative regulation to customs enforcement. After TGA notifies Customs, goods are handled as prohibited imports and exports, and the risk escalates from administrative penalties to detained cargo. The impact on supply chain scheduling far exceeds the fine itself. For planning purposes this means customs risk should be treated as a logistics risk, with entry status checks built into shipment scheduling instead of being left to the broker at the border.

Insight 3: the 20 working days in regulation 5.12 are an advance duty. Specific devices must complete notification before the import action occurs. Filing the notice after the goods have arrived at port does not constitute compliance. Forwarders should be instructed to release nothing until the notification receipt is on file, and the 20 working days lead time should be built into the standard shipping calendar for the affected categories.

One structural point closes the picture. Because the importer is itself a sponsor under section 3(1) whenever it imports on its own account, the import compliance file and the sponsor obligations file are ultimately the same file. Companies that separate them — customs documents in one drawer, sponsor duties in another — end up with two half-pictures of the same legal exposure, and it is usually the half-picture that nobody owns which produces the offence.

In day-to-day operation, the practical deliverable is a standing entry-status report: one page listing each active entry, its covered models, its annual charge status and the expiry or cancellation risks attached to it. Reviewed before each shipment cycle, that single page converts the legal framework above into a routine logistics checkpoint.

4. Practical recommendations

• Maintain a three-way reconciliation ledger of entry, model and import batch, so that every imported batch falls within a valid entry.
• Complete the regulation 5.12 notification 20 working days before shipment for specific devices, and include the notification receipt in the customs clearance document pack.
• Share entry status with freight forwarders and customs brokers, and set automatic blocking when an entry lapses (for example, through cancellation for unpaid annual charges).
• For devices involving poisons, additionally check the current Poisons Standard (regulation 5.13).

5. Verification checklist

• □ Every import batch has been checked to fall within a valid ARTG entry
• □ The 20 working days advance notice under regulation 5.12 has been completed for specific devices
• □ Entry status is shared with freight forwarders and brokers, with lapse blocking in place
• □ Devices containing poisons have been checked against the Poisons Standard
• □ No reliance on an “import licence” exists; legality rests on the entry

Regulatory information verified as of 29 October 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team coordinates Australian sponsor arrangements, ARTG annual charges, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com